Incentivio is a developer of an intelligent guest engagement platform designed to enhance the restaurant experience in the digital age. The platform aims to help restaurants acquire new customers, increase visit frequency and spending, and foster customer loyalty. By leveraging technology, Incentivio enables restaurants to build meaningful relationships with their guests, ultimately driving digital revenue. Additionally, the platform helps reduce operational costs and generates incremental revenue, positioning restaurants to thrive in a competitive market.
Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, that focuses on the early detection of cancer through non-invasive blood tests. Founded in 2018, the company utilizes advanced technologies such as artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in patients' blood. By leveraging machine learning, Delfi develops innovative testing systems aimed at recognizing cancer-associated cell-free DNA fragments, thereby enabling healthcare professionals to detect cancer at its most treatable stage. This approach facilitates timely and effective treatment options, ultimately aiming to improve patient outcomes and recovery speed.
Developer of a decentralized identity platform designed to augment identity verification The company's platform has a full-stack verifiable credential and digital wallet that uses digital credentials based on open standards that can be integrated into the existing system as well as offers custom services, enabling clients and organizations with digital identity and safety.
AssetWatch is a wireless power technology company that specializes in converting radio frequency (RF) energy into direct current (DC) power for electronic devices. Founded in 2014 and based in Columbus, Ohio, the company has developed a flexible and efficient technology that captures usable power from various ISM radio bands, including signals from Wi-Fi, Bluetooth, and LTE. Its innovative solutions are designed to support low-power wireless sensors and address the limitations of battery life in modern electronic devices, particularly within the expanding Internet of Things (IoT) sector. By providing state-of-the-art wireless power solutions, AssetWatch aims to enhance user experiences, eliminate maintenance issues, and improve the overall functionality of contemporary products. The company's team consists of skilled electrical engineers and experienced business leaders committed to advancing wireless power technology in the marketplace.
MicroTransponder, Inc. is a medical device company focused on developing and commercializing neurostimulation devices aimed at treating neurological diseases. The company offers innovative therapies, including the Serenity System for tinnitus and the Paired VNS System, which addresses chronic pain and post-stroke upper limb mobility issues. Founded in 2007, MicroTransponder is headquartered in Dallas, Texas, and aims to enhance treatment options for various neurological conditions through its advanced technology.
Developer of an all-in-one commerce & content platform designed to serve as a bridge between existing Web2 services and the Web3 ecosystem. The company's platform helps the creator turn their personal website into a creative library & digitally-native commerce platform, and expands the accessibility of Web3 to all creators, enabling them to build an interactive website, portfolio, or link-in-bio in minutes for every drop.
Brimstone Energy is a hardware cleantech startup that aims to reduce CO2 emissions through innovative technologies.
DeepSurface Security is a cybersecurity company based in Portland, Oregon, specializing in automated Predictive Vulnerability Management. The firm provides a suite of tools designed to assist cybersecurity teams in identifying, analyzing, and prioritizing vulnerabilities based on their potential risk to enterprise networks. By utilizing advanced rules for comprehensive context gathering, DeepSurface predicts where attackers could inflict the most damage, thereby streamlining the vulnerability management process. Trusted by enterprise organizations, DeepSurface aims to enhance the efficiency and effectiveness of cybersecurity efforts, enabling teams to focus on critical threats. The company is privately held and has received funding from Cascade Seed Fund, SeaChange Fund, and Voyager Capital.
Circonus, Inc. is a machine data intelligence platform that specializes in real-time handling of IoT and IT infrastructure data. Founded in 2010 and headquartered in Fulton, Maryland, the company provides solutions that allow organizations to collect, store, manage, and analyze vast streams of data. Circonus enables users to visualize and monitor their data in real time, facilitating the identification and resolution of IT infrastructure issues. Its platform supports various functionalities, including predictive analytics, trend monitoring, and operational insights, making it suitable for applications in infrastructure monitoring, IoT, cloud monitoring, and DevOps. Circonus serves diverse industries such as advertising technology, entertainment, financial technology, logistics, and smart utilities, helping them optimize operations and enhance user experiences through accurate and timely data.
Antiva Biosciences is a biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by HPV infection. The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego. They are now Antiva Biosciences which is headquartered in South San Francisco.
ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and develop first-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations. ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing. The company was founded in 2015 and is based in Dallas, Texas.
Transeo is a cloud-based educational solution that helps students and administrators track, report, and celebrate their community service learning experiences. We make hour verification, logging, and report generation easy for students and counselors. We are helping schools and districts move away from paper-based processes so counselors can invest more quality time with the people who matter the most: students.
Malbek is an AI-driven platform specializing in enterprise contract lifecycle management, encompassing all stages from request and redlining to signature and commitment tracking. Its cloud-based solution simplifies the contract authoring process, allowing businesses to close deals more quickly and efficiently. By enhancing contract visibility and enabling easy searches, Malbek helps organizations manage increasing workloads while maximizing contract profitability. The platform features a user-friendly interface that is as straightforward as using an ATM, allowing both end-users and application administrators to customize their experience without the need for coding. This innovative approach aims to accelerate contract cycle times and improve overall efficiency in contract management.
DeepHow is an AI-powered learning platform founded in 2018 and headquartered in New York City. It specializes in providing solutions for skilled workforce training in manufacturing, service, and repair sectors. The platform converts complex technical manuals for industrial machine servicing into interactive, step-by-step instructions. This transformation allows clients to perform inspection, repair, and maintenance tasks more effectively, significantly reducing errors and minimizing the need for rework. Through its innovative approach, DeepHow aims to enhance the efficiency and accuracy of technical training in various industries.
Operator of a biopharmaceutical company intended to discover and develop next-generation medicines for neurodegenerative diseases. The company is focused on developing small-molecule activators of glucocerebrosidase and advanced programs targeting the innate immune system that can accelerate the progression of several neurological diseases, enabling healthcare professionals to transform the lives of patients with treatments for various ailments.
Corelight, Inc. provides network visibility solutions aimed at enhancing information security for enterprises, government entities, and educational institutions. Founded in 2013 and headquartered in San Francisco, California, the company specializes in network traffic analysis to help security professionals understand network behavior and detect cyberattacks. Corelight's offerings include sensors, a fleet manager, and software products designed to secure networks. Central to its solution is Bro, an open-source network analysis framework that delivers actionable, real-time data for security teams globally. In addition to its headquarters, Corelight maintains offices in Santa Clara, California, and Columbus, Ohio.
Effector Therapeutics is a biotechnology company based in San Diego, California, that specializes in the development of small molecule drugs aimed at treating cancer and other serious diseases. Founded in 2012, the company focuses on creating selective translation regulators that target the regulation of protein synthesis, a critical process in tumor growth and survival. By selectively blocking dysregulated translation, Effector Therapeutics aims to inhibit cancer cell proliferation while providing a potent and targeted therapeutic approach. This innovative strategy positions the company to potentially deliver new and effective treatments to patients facing challenging health conditions.
DiCE Therapeutics, founded in 2013 and based in Menlo Park, California, specializes in developing a platform for the discovery of novel small molecules aimed at targets that have previously been difficult to address in the pharmaceutical sector. The company utilizes innovative technology that extends directed evolution, allowing for the direct translation of DNA-encoded information into organic compounds, thereby streamlining the traditionally labor-intensive processes of medicinal chemistry. This platform not only serves the pharmaceutical industry but also has applications in agriculture and materials sciences. The founding team includes notable figures such as Stanford Professor Pehr Harbury, who developed the core technology, and other experienced professionals from various sectors, contributing to the company's mission of transforming drug discovery and development.
ANRA Technologies, LLC specializes in developing a cloud-based platform for commercial drone operations. Founded in 2014 and based in Tysons, Virginia, the company offers various solutions including DroneOSS, which provides real-time flight planning, automated notifications, autonomous execution, and data analytics. The platform also facilitates the integration of processed data back into enterprise systems. Additionally, ANRA Technologies features the DroneUSS UTM platform for unmanned operations and SmartSkies CTR, which allows drone pilots to secure approvals for operations in controlled airspace through a mobile application or web portal. The company further extends its services by offering consultancy in urban air mobility and integration of drone operations, catering to the needs of commercial entities managing multiple unmanned aerial vehicles.
HUED is a platform that diversifies the patient/doctor connection by connecting patients with diverse healthcare providers.
Sonoma Biotherapeutics develops adoptive Treg cell therapies aimed at treating autoimmune and degenerative diseases. The company employs advanced genome editing and target-specific cell therapy to create therapeutic solutions that promote self-tolerance and mitigate harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded in 2019 and headquartered in South San Francisco, California, with an additional office in Seattle, Washington, Sonoma Biotherapeutics combines expertise in Treg biology and proprietary methodologies to advance its therapeutic platform, focusing on developing disease-modifying and potentially curative treatments.
Verve Motion specializes in the development of lightweight wearable exo-suits aimed at enhancing the safety and comfort of workers engaged in physically demanding tasks. By integrating robotics, apparel design, and movement science, the company creates innovative textile-based solutions that adapt to the movements of the wearer. These exo-suits provide support by delivering force at critical moments while remaining nonrestrictive, thereby promoting a safer work environment. Additionally, Verve Motion's designs contribute to a more restful experience for workers during their off-hours.
Operator of a biotechnology platform intended to increase binding affinity and improve consistency to help create personalized, precision cancer vaccines for patients of all backgrounds. The company's platform focuses on developing a single-molecule, massively parallel, de novo next-generation protein sequencing platform, enabling scientists and researchers to develop novel therapeutics and diagnostics and ultimately understand human biology and disease.
Ostendio, Inc. specializes in healthcare information security and risk management solutions tailored for healthcare organizations and medical device manufacturers. The company's flagship product, MyVirtualComplianceManager (MyVCM), is a cloud-based platform designed to streamline the development, management, and demonstration of information security frameworks. MyVCM adopts a unique bottom-up approach, engaging all employees in the security and compliance processes, while providing a comprehensive view of an organization’s cybersecurity program. This allows clients to effectively report their security posture to stakeholders. In addition to MyVCM, Ostendio offers services such as performance testing, quality management support, cybersecurity training, and risk assessment program development. Founded in 2013 and headquartered in Arlington, Virginia, Ostendio serves a diverse clientele across North America, Europe, the Middle East, and Australia.
Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, founded in 2015. The company is focused on developing innovative cancer therapies that target monoPARP proteins, which are essential regulators of cancer cell survival. Ribon's scientific founders have made significant contributions to the understanding of PARPs, or poly(ADP-ribose) polymerases, and their roles in cancer. Leveraging this expertise, Ribon is establishing a proprietary drug discovery platform aimed at exploring the molecular actions and biological functions of monoPARPs. This platform supports the creation of a pipeline of therapeutics that selectively target these proteins to potentially treat cancer and other diseases. Ribon Therapeutics is supported by notable life science investors, enhancing its capability to advance its research and development efforts.
Interius BioTherapeutics
Series A in 2021
Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer.
Pliant.io, Inc. is a technology company that specializes in infrastructure automation, providing a platform designed for IT operations to efficiently plan, build, and deploy API-level automations. Founded in 2017 and based in Boston, Massachusetts, Pliant offers an orchestration, automation, and response (OAR) platform that simplifies the development of IT automation solutions. Its platform features visual representations and low-code building blocks, enabling developers to automate complex processes across various domains. Use cases for Pliant's technology include virtual machine provisioning, server auditing and remediation, IT service management orchestration, hybrid network configuration, and application delivery and security. By streamlining automation, Pliant helps organizations respond to the evolving demands of their business processes while reducing human error and enhancing overall efficiency.
Strategikon Pharma, Inc. is a technology firm that specializes in the design and development of software solutions aimed at optimizing the outsourcing processes in the pharmaceutical industry. Its flagship product, Clinical Maestro, is a cloud-based platform that facilitates end-to-end management of clinical business operations, including planning, outsourcing, and financial management of clinical trials. This software creates a collaborative virtual environment that enhances communication and data integration between pharmaceutical companies and their service providers, moving away from traditional, labor-intensive methods such as Excel. By providing tools for clinical financial management, vendor performance metrics, and contract lifecycle management, Clinical Maestro enables biopharmaceutical firms to streamline their operations and reduce costs significantly. Founded in 2016 and headquartered in San Rafael, California, Strategikon also offers consulting services to support the establishment of clinical business operations for new entrants in the field.
ExecOnline, Inc. is a New York-based company that offers a learning platform tailored for business executives, focusing on online executive education programs. Incorporated in 2012, ExecOnline partners with elite business schools to provide a dynamic, interactive online learning environment that enhances professional development for executives at major corporations. The platform features on-demand video lectures, self-paced application exercises, and opportunities for live interaction with professors and peers, allowing users to gain critical insights and practical solutions at a fraction of the cost of traditional on-campus programs. ExecOnline supports its academic partners with a customizable learning management system and comprehensive sales and marketing capabilities, facilitating the development of high-quality online executive education offerings.
Hack The Box Ltd. is an online platform established in 2017, located in Folkestone, United Kingdom, that focuses on enhancing skills in penetration testing and cybersecurity. The platform provides a variety of challenges that simulate real-world scenarios, allowing users to engage in capture the flag style exercises. This interactive approach enables individuals, universities, and businesses to learn new techniques and improve their hacking abilities, addressing the growing need for cybersecurity expertise in various sectors.
Fortis Therapeutics is a biotechnology company specializing in immuno-oncology, with a focus on developing innovative antibody-drug conjugate therapies for late-stage multiple myeloma and prostate cancer. The company was established based on technology exclusively licensed from the University of California, San Francisco, and developed in the laboratory of Dr. Bin Liu. Fortis Therapeutics aims to enhance treatment options for patients suffering from advanced adenocarcinoma and neuroendocrine cancer, leveraging its proprietary platform to create targeted therapies that improve clinical outcomes in late-stage cancer treatment.
Connected2Fiber, Inc. provides a location-based insights platform tailored for network buyers and sellers in the United States. Founded in 2015 and based in Hopkinton, Massachusetts, the company offers a suite of solutions designed to enhance transparency and efficiency in the network industry. Its key offerings include the Connected World module, which visualizes fiber networks alongside market context, and the Building Manager module, which facilitates the management of various connected assets. The platform also features Building Intelligence for visualizing OnNet buildings and a Building List Manager for efficient contact and program management. Additionally, Connected2Fiber provides a Configure, Price, Quote (CPQ) tool that automates price quoting with detailed, location-based insights. The company's services cater to a range of sectors, including local exchange carriers, cable companies, competitive local exchange carriers, and municipal networks, enabling them to improve their marketing investments and operational outcomes.
Refraction AI, Inc., an autonomous delivery robot company, builds and deploys robotic platforms to provide goods delivery in urban areas. It offers The REV-1, a delivery robotic vehicle that picks up goods from restaurants, pharmacies, and grocery stores, and bring them directly to the customers’ house. Refraction AI, Inc. was founded in 2017 and is based in Ann Arbor, Michigan.
EGenesis Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in New York. Founded in 2015, the company specializes in gene editing and genome engineering, focusing on the development of human-compatible organs, tissues, and cells for transplantation. EGenesis employs advanced gene editing techniques to create transplantable cells and solid organs, specifically targeting therapeutic applications in kidney and islet cell transplantation. By leveraging its innovative platform, the company aims to transform the field of organ transplantation, providing safe and effective solutions for patients with life-threatening diseases globally.
Artizan Biosciences develops small molecule drugs targeting human diseases, utilizing its IgA-SEQ technology platform to identify disease-driving bacteria within the intestinal microbiota. Founded in 2016 and headquartered in New Haven, Connecticut, the company focuses on creating new and potentially curative treatments. With a commitment to advancing pharmaceutical drug development, Artizan Biosciences aims to address unmet medical needs through innovative approaches in biotechnology.
Cyteir Therapeutics, Inc. focuses on developing innovative therapeutics that harness the biology of DNA repair to treat cancer and address autoimmune diseases through synthetic lethality. The company manufactures targeted therapeutics designed to induce the self-destruction of diseased cells by overwhelming them with DNA damage. Utilizing an integrated drug development platform, Cyteir aims to balance DNA damage and repair mechanisms to achieve therapeutic effects. Its diverse pipeline includes small molecule therapeutics intended for various applications, particularly in hematological malignancies, solid tumors, and chronic autoimmune disorders. Founded in 2012 and headquartered in Lexington, Massachusetts, Cyteir Therapeutics is committed to overcoming significant challenges in oncology, such as minimizing side effects, reducing therapy resistance, and promoting the self-destruction of cancerous cells.
Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, that focuses on the early detection of cancer through non-invasive blood tests. Founded in 2018, the company utilizes advanced technologies such as artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in patients' blood. By leveraging machine learning, Delfi develops innovative testing systems aimed at recognizing cancer-associated cell-free DNA fragments, thereby enabling healthcare professionals to detect cancer at its most treatable stage. This approach facilitates timely and effective treatment options, ultimately aiming to improve patient outcomes and recovery speed.
Dina Care is a healthcare company dedicated to enhancing patient outcomes by facilitating connections between personal caregivers and care providers. Founded in 2015 and based in Chicago, Illinois, Dina Care's platform enables real-time communication among healthcare teams, ensuring that patients and families remain informed about care updates even when not physically together. The company focuses on empowering consumers, health plans, and accountable care organizations to explore a growing range of in-home health services that contribute to well-being. Utilizing AI technology, Dina Care helps caregivers gather valuable data from the home environment to identify unmet needs and recommend evidence-based interventions. This approach not only supports patients in their recovery but also promotes ongoing health maintenance, ultimately aiming to keep individuals healthier, safer, and happier in their homes.
DiCE Therapeutics, founded in 2013 and based in Menlo Park, California, specializes in developing a platform for the discovery of novel small molecules aimed at targets that have previously been difficult to address in the pharmaceutical sector. The company utilizes innovative technology that extends directed evolution, allowing for the direct translation of DNA-encoded information into organic compounds, thereby streamlining the traditionally labor-intensive processes of medicinal chemistry. This platform not only serves the pharmaceutical industry but also has applications in agriculture and materials sciences. The founding team includes notable figures such as Stanford Professor Pehr Harbury, who developed the core technology, and other experienced professionals from various sectors, contributing to the company's mission of transforming drug discovery and development.
Neuros Medical, Inc. is a neuromodulation company based in Willoughby Hills, Ohio, that specializes in developing proprietary neurostimulation therapies to address unmet medical needs for patients globally. The company’s flagship technology, Electrical Nerve Block, targets the elimination of chronic pain associated with various conditions, including neuroma, residual limb pain, chronic post-surgical pain, and chronic migraines. Additionally, Neuros Medical offers the Neuros Altius System, which features an implantable generator with an integrated rechargeable battery, a cuff electrode, and external devices designed to enhance treatment outcomes. Founded in 2008, the company aims to provide innovative solutions for chronic pain management.
CIPIO Inc. develops a customer intelligence platform designed for B2C businesses, focusing on enhancing customer engagement and retention. Its flagship product, CIPIO, acts as an intelligent assistant that provides hyper-personalized predictions and recommendations tailored to individual customer journeys. By integrating member data and engagement metrics with augmented intelligence, the platform aims to improve acquisition, retention, and revenue growth for its clients. Specifically targeted towards the fitness industry, CIPIO assists businesses in identifying the most effective customers, products, channels, and offers, thereby facilitating increased engagement and reducing churn. Founded in 2019, CIPIO operates out of Fairfax, Virginia, with additional offices in Redwood City, California, and Bengaluru and Ahmedabad, India.
Atsena Therapeutics is a clinical-stage gene therapy company dedicated to developing ocular gene therapies aimed at reversing or preventing blindness. The company focuses on treating prominent forms of Leber congenital amaurosis and Usher syndrome. Utilizing adeno-associated virus technology, Atsena's pipeline is designed to address the challenges associated with inherited retinal diseases, providing innovative solutions to restore vision and improve the quality of life for patients affected by these conditions.
Indico Data Solutions, Inc. is a Boston-based company that specializes in developing artificial intelligence solutions for automating the processing of unstructured content. Founded in 2013, Indico's platform allows enterprises to create customized machine learning models using smaller datasets, effectively enhancing the efficiency of labor-intensive document-based workflows. By focusing on automating tedious back-office tasks, Indico enables organizations to extract valuable insights from unstructured content, such as text and images. The company's innovative approach, known as transfer learning, empowers users to train machine learning models with significantly less data than traditional methods require. This capability helps businesses overcome common barriers to AI adoption, ultimately transforming their document processing into more profitable operations.
boodleAI delivers people-based predictive analytics using the organization's data, third party data, and AI/machine learning to enable: (1) nonprofits to acquire, grow, and retain donors (boodle.ai); (2) veteran political candidates to raise contributions (adjutant.ai); and (3) B2C commercial companies to acquire, grow, and retain customers (guidon.ai).
Menlo Security, Inc. is a cybersecurity company that offers a cloud-based isolation platform designed to protect organizations from cyberattacks by eliminating malware threats from websites, documents, and emails. The platform safely executes all web content in the cloud, allowing users to interact with online resources without risk. Menlo Security serves a diverse clientele, including Fortune 500 companies and financial services institutions, through a network of resellers both in the United States and internationally. Founded in 2012 and headquartered in Mountain View, California, the company has expanded its operations across various regions, including North America, EMEA, Australia, New Zealand, Japan, APAC, and DACH. The firm has received backing from notable investors, indicating strong confidence in its innovative approach to cybersecurity.
Menlo Security, Inc. is a cybersecurity company that offers a cloud-based isolation platform designed to protect organizations from cyberattacks by eliminating malware threats from websites, documents, and emails. The platform safely executes all web content in the cloud, allowing users to interact with online resources without risk. Menlo Security serves a diverse clientele, including Fortune 500 companies and financial services institutions, through a network of resellers both in the United States and internationally. Founded in 2012 and headquartered in Mountain View, California, the company has expanded its operations across various regions, including North America, EMEA, Australia, New Zealand, Japan, APAC, and DACH. The firm has received backing from notable investors, indicating strong confidence in its innovative approach to cybersecurity.
Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.
Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.
Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.
Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.
DrayNow, Inc., founded in 2017 and based in Pipersville, Pennsylvania, operates as a technology company specializing in the intermodal freight sector. It offers a real-time online marketplace that connects intermediaries with carriers, facilitating the efficient management of intermodal freight transportation. By leveraging advanced technology, DrayNow enables users to maintain constant visibility of shipments, compare rates, view load details, and select available loads in real-time. This innovative platform optimizes the first and last mile of intermodal logistics, enhancing operational efficiency and helping companies achieve higher levels of capacity, service, and profitability.
MarginEdge Co. develops food and beverage tracking and analytics software for restaurants. It offers MarginEdge, a software solution for invoice management, recipe and product pricing, and food costs optimization. The company’s software also automates processes, connects systems; and streamlines key activities, such as inventory, cost-tracking, ordering, and recipes. MarginEdge Co. was formerly known as Invioso Co. The company was founded in 2015 and is based in Falls Church, Virginia.
Palladio Biosciences, Inc. is a biotechnology company focused on developing transformative medicines for orphan diseases of the kidney. Founded in 2015 and based in Horsham, Pennsylvania, the company is in the clinical stage and specializes in therapeutics aimed at renal diseases, particularly polycystic kidney disease (PKD). One of its key developments is Lixivaptan, a selective vasopressin V2 receptor antagonist designed to treat PKD, a life-threatening genetic disorder characterized by the growth of numerous fluid-filled cysts in the kidneys. Palladio Biosciences aims to provide innovative treatment options that can help prevent the progression of kidney diseases.
Palladio Biosciences, Inc. is a biotechnology company focused on developing transformative medicines for orphan diseases of the kidney. Founded in 2015 and based in Horsham, Pennsylvania, the company is in the clinical stage and specializes in therapeutics aimed at renal diseases, particularly polycystic kidney disease (PKD). One of its key developments is Lixivaptan, a selective vasopressin V2 receptor antagonist designed to treat PKD, a life-threatening genetic disorder characterized by the growth of numerous fluid-filled cysts in the kidneys. Palladio Biosciences aims to provide innovative treatment options that can help prevent the progression of kidney diseases.
E-Scape Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies for neurodegenerative diseases. Established in 2015 and headquartered in South San Francisco, California, the company aims to improve the lives of patients suffering from conditions such as Alzheimer’s disease, Parkinson’s disease, and sphingolipid storage disorders. E-Scape Bio is advancing a pipeline of therapeutics that target specific genetic drivers of these diseases, including ESB1609, a small molecule S1P5 receptor agonist for CNS lysosomal storage disorders, and ESB5070, a kinase inhibitor designed for Parkinson’s disease patients with the LRRK2 G2019S variant. Additionally, the company is developing a program targeting ApoE4 in Alzheimer’s disease, emphasizing its commitment to precision medicine in treating genetically defined subpopulations.
Escient Pharmaceuticals, Inc., a biotechnology company, develops and manufactures G protein-coupled receptor (GPCR)-targeted drugs for treating neuro-immuno-inflammatory and autoreactive diseases. The company focuses on unleashing the therapeutic potential of specific orphan GPCRs, including the novel family of Mas-Related G-Protein Receptors (Mrgprs) for neuro-immuno-inflammatory and autoreactive diseases. Escient Pharmaceuticals, Inc. was formerly known as Mas Therapeutics, Inc. The company was founded in 2017 and is based in San Diego, California.
Nido Biosciences, Inc., founded in 2018 and based in Boston, Massachusetts, operates in the healthcare services sector. The company specializes in biotechnology and personal health, aiming to innovate within these fields. Currently in stealth mode, Nido Biosciences is focused on developing solutions that address unmet needs in healthcare and personal health management.
HelloTeam is a cloud-based engagement and talent management platform aimed at enhancing employee engagement and retention. The platform provides tools for driving employee goals, performance, and recognition, while also facilitating the development of data-driven people strategies. By leveraging real-time insights and analytics, HelloTeam helps organizations create a work environment where employees feel seen, heard, and valued. This focus on employee experience contributes to a more engaged and connected workforce, ultimately fostering a positive organizational culture.
SiFive, Inc. is a semiconductor company that specializes in designing and manufacturing chips, particularly focused on RISC-V architecture. Founded in 2015 and headquartered in San Mateo, California, with additional offices worldwide, SiFive develops multi-core application processors, embedded microcontrollers, and system-on-chip (SoC) products tailored for various applications, including IoT and wearables. The company provides software development kits, toolchains, and utilities to facilitate the development of RISC-V devices, enhancing the efficiency and affordability of hardware design. By leveraging open-source principles and software automation, SiFive aims to accelerate innovation in the semiconductor industry, enabling both large and small businesses to bring new hardware solutions to market more rapidly.
SiFive, Inc. is a semiconductor company that specializes in designing and manufacturing chips, particularly focused on RISC-V architecture. Founded in 2015 and headquartered in San Mateo, California, with additional offices worldwide, SiFive develops multi-core application processors, embedded microcontrollers, and system-on-chip (SoC) products tailored for various applications, including IoT and wearables. The company provides software development kits, toolchains, and utilities to facilitate the development of RISC-V devices, enhancing the efficiency and affordability of hardware design. By leveraging open-source principles and software automation, SiFive aims to accelerate innovation in the semiconductor industry, enabling both large and small businesses to bring new hardware solutions to market more rapidly.
Aerovate Therapeutics is a clinical-stage biotechnology company based in Boston, Massachusetts, dedicated to developing treatments for patients with rare cardiopulmonary diseases. The company's primary focus is on advancing AV-101, a proprietary inhaled dry powder formulation of the drug imatinib, designed to treat pulmonary arterial hypertension (PAH). This innovative delivery method targets diseased lung tissues directly, minimizing systemic side effects often associated with traditional therapies. Founded in 2018 and initially incubated by RA Capital Management, Aerovate aims to provide meaningful improvements to the lives of those affected by these serious conditions.
Private Equity Round in 2020
Katabat Corporation specializes in providing digital debt collection software and solutions tailored for credit-based consumer lenders. Its flagship products include Katabat Restore, a SaaS-based debt management and collections platform that streamlines compliance, customer communications, and debt recovery processes. Additionally, the company offers Katabat Liberate, which automates workflows to enhance operational efficiency, and Katabat Unite, designed to optimize customer marketing communications and manage multichannel campaigns. Katabat's solutions address various needs, including unified collections, digital onboarding, and customer lifecycle management, serving sectors such as enterprise banking, alternative lending, and utilities. Established in 2000 and headquartered in Wilmington, Delaware, the company also maintains offices in the United Kingdom and Australia. Katabat operates as a subsidiary of Bridgeforce, Inc.
Censys, Inc. is a cybersecurity company specializing in internet scanning and asset identification solutions. Founded in 2017 and based in Ann Arbor, Michigan, Censys provides an internet device search engine that allows users to discover and analyze devices connected to the Internet, including computers, servers, and smart devices. The platform is utilized for various applications such as attack surface management, monitoring remote workforces, and identifying potential threats. Censys is recognized for delivering real-time visibility and risk assessments, making it a valuable resource for researchers, corporations, and government entities. The company's data-driven security solutions are employed by notable organizations, including FireEye, Google, NATO, and the U.S. Department of Homeland Security, to enhance their cybersecurity measures and proactively address threats.
Censys, Inc. is a cybersecurity company specializing in internet scanning and asset identification solutions. Founded in 2017 and based in Ann Arbor, Michigan, Censys provides an internet device search engine that allows users to discover and analyze devices connected to the Internet, including computers, servers, and smart devices. The platform is utilized for various applications such as attack surface management, monitoring remote workforces, and identifying potential threats. Censys is recognized for delivering real-time visibility and risk assessments, making it a valuable resource for researchers, corporations, and government entities. The company's data-driven security solutions are employed by notable organizations, including FireEye, Google, NATO, and the U.S. Department of Homeland Security, to enhance their cybersecurity measures and proactively address threats.
Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.
Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.
StreetLight Data, Inc. specializes in cloud-based analytics solutions aimed at enhancing transportation management for both companies and government entities. Its primary product, StreetLight InSight, is an online platform that analyzes mobility patterns through Big Data, transforming anonymous location data from mobile devices into actionable insights for transportation engineers, urban planners, and property developers. Additionally, the company offers RouteScience, which organizes disparate location data into cohesive travel patterns. Founded in 2010 and headquartered in San Francisco, California, with additional locations in Richmond, Virginia, and Vancouver, Canada, StreetLight Data enables users to make informed decisions regarding infrastructure deployment and transportation planning, ultimately contributing to the development of smarter cities.
Malbek is an AI-driven platform specializing in enterprise contract lifecycle management, encompassing all stages from request and redlining to signature and commitment tracking. Its cloud-based solution simplifies the contract authoring process, allowing businesses to close deals more quickly and efficiently. By enhancing contract visibility and enabling easy searches, Malbek helps organizations manage increasing workloads while maximizing contract profitability. The platform features a user-friendly interface that is as straightforward as using an ATM, allowing both end-users and application administrators to customize their experience without the need for coding. This innovative approach aims to accelerate contract cycle times and improve overall efficiency in contract management.
Atsena Therapeutics is a clinical-stage gene therapy company dedicated to developing ocular gene therapies aimed at reversing or preventing blindness. The company focuses on treating prominent forms of Leber congenital amaurosis and Usher syndrome. Utilizing adeno-associated virus technology, Atsena's pipeline is designed to address the challenges associated with inherited retinal diseases, providing innovative solutions to restore vision and improve the quality of life for patients affected by these conditions.
ReCode Therapeutics is a biopharmaceutical company that focuses on developing precision medicines for pulmonary diseases, particularly targeting rare conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company has created a non-viral lipid nanoparticle platform that facilitates the targeted delivery of genetic therapies. This innovative technology aims to deliver corrective or disease-modifying therapies to specific organs and tissues, addressing the limitations of current gene therapy methods. By improving the precision of drug delivery, ReCode Therapeutics seeks to provide new treatment options for patients with unmet medical needs, particularly in the realm of life-limiting respiratory diseases.
ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and develop first-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations. ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing. The company was founded in 2015 and is based in Dallas, Texas.
Circonus, Inc. is a machine data intelligence platform that specializes in real-time handling of IoT and IT infrastructure data. Founded in 2010 and headquartered in Fulton, Maryland, the company provides solutions that allow organizations to collect, store, manage, and analyze vast streams of data. Circonus enables users to visualize and monitor their data in real time, facilitating the identification and resolution of IT infrastructure issues. Its platform supports various functionalities, including predictive analytics, trend monitoring, and operational insights, making it suitable for applications in infrastructure monitoring, IoT, cloud monitoring, and DevOps. Circonus serves diverse industries such as advertising technology, entertainment, financial technology, logistics, and smart utilities, helping them optimize operations and enhance user experiences through accurate and timely data.
PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.
ANRA Technologies, LLC specializes in developing a cloud-based platform for commercial drone operations. Founded in 2014 and based in Tysons, Virginia, the company offers various solutions including DroneOSS, which provides real-time flight planning, automated notifications, autonomous execution, and data analytics. The platform also facilitates the integration of processed data back into enterprise systems. Additionally, ANRA Technologies features the DroneUSS UTM platform for unmanned operations and SmartSkies CTR, which allows drone pilots to secure approvals for operations in controlled airspace through a mobile application or web portal. The company further extends its services by offering consultancy in urban air mobility and integration of drone operations, catering to the needs of commercial entities managing multiple unmanned aerial vehicles.
IonQ, Inc. specializes in the development of general-purpose quantum information computers, utilizing a unique trapped ion approach. The company's technology combines high physical performance, perfect qubit replication, and optical networkability, enabling the creation of scalable quantum computers that surpass the limitations of classical computing. These advancements leverage phenomena such as superposition and entanglement, which are critical at the atomic scale. Founded in 2015 and headquartered in College Park, Maryland, IonQ aims to support a wide range of applications across various industries with its powerful and versatile quantum computing solutions.
MarginEdge Co. develops food and beverage tracking and analytics software for restaurants. It offers MarginEdge, a software solution for invoice management, recipe and product pricing, and food costs optimization. The company’s software also automates processes, connects systems; and streamlines key activities, such as inventory, cost-tracking, ordering, and recipes. MarginEdge Co. was formerly known as Invioso Co. The company was founded in 2015 and is based in Falls Church, Virginia.
ArsenalBio is a programmable cell therapy company focused on creating effective and accessible immune cell therapies, particularly for cancer patients. Established in 2019, the company integrates advanced technologies, including CRISPR-based genome engineering, synthetic biology, and machine learning, to revolutionize the discovery and development of immune cell therapies. ArsenalBio employs a comprehensive research and development approach to produce multifunctional T-cell therapies, utilizing the precise insertion of large synthetic DNA sequences. The company's mission is to enhance the efficacy and safety of immune cell therapies while reducing costs for providers and expanding access for patients. Through its innovative framework, ArsenalBio aims to significantly improve treatment outcomes for a broader patient population.
Cyteir Therapeutics, Inc. focuses on developing innovative therapeutics that harness the biology of DNA repair to treat cancer and address autoimmune diseases through synthetic lethality. The company manufactures targeted therapeutics designed to induce the self-destruction of diseased cells by overwhelming them with DNA damage. Utilizing an integrated drug development platform, Cyteir aims to balance DNA damage and repair mechanisms to achieve therapeutic effects. Its diverse pipeline includes small molecule therapeutics intended for various applications, particularly in hematological malignancies, solid tumors, and chronic autoimmune disorders. Founded in 2012 and headquartered in Lexington, Massachusetts, Cyteir Therapeutics is committed to overcoming significant challenges in oncology, such as minimizing side effects, reducing therapy resistance, and promoting the self-destruction of cancerous cells.
Brazen Technologies, Inc. is a company that specializes in chat-based recruiting software and virtual event platforms. Founded in 2007 and headquartered in Arlington, Virginia, Brazen offers a range of features including live chat, scheduled chat, chat events, and AI-powered chatbots to enhance engagement during online interactions. The platform facilitates virtual hiring events and online career fairs, allowing organizations to connect with job candidates, students, and alumni. By providing tools for engagement and relationship building, Brazen helps employers identify and hire top talent while supporting professionals in discovering new career opportunities and networking effectively. The company has evolved since its inception but remains committed to its mission of empowering individuals to achieve their career goals through innovative technology.
Earnest Research is a data innovation company driven to change the way professionals understand consumer and business behavior. Working with world-class data partners, we transform raw data into a source for business and investment professionals to ask better questions so they can make better decisions.
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company based in Blacksburg, Virginia, specializing in the development of oral therapeutics for autoimmune diseases. Founded in 2017, the company focuses on innovative treatments for conditions such as inflammatory bowel disease (IBD), Crohn's disease, and ulcerative colitis. Its lead product candidate, NX-13, is a novel, gut-selective agonist targeting the NLRX1 pathway. The company also has a diverse pipeline that includes other internally discovered compounds aimed at novel immunometabolic pathways. By developing first-in-class therapeutics, Landos Biopharma seeks to provide effective treatment options for patients suffering from autoimmune conditions.
Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company specializes in developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By focusing on these mechanisms, Cleave Therapeutics aims to create enzyme inhibitors that can effectively treat cancer and neurodegenerative diseases. Its research efforts are directed toward discovering innovative therapies that may improve patient outcomes in oncology.
Connected2Fiber, Inc. provides a location-based insights platform tailored for network buyers and sellers in the United States. Founded in 2015 and based in Hopkinton, Massachusetts, the company offers a suite of solutions designed to enhance transparency and efficiency in the network industry. Its key offerings include the Connected World module, which visualizes fiber networks alongside market context, and the Building Manager module, which facilitates the management of various connected assets. The platform also features Building Intelligence for visualizing OnNet buildings and a Building List Manager for efficient contact and program management. Additionally, Connected2Fiber provides a Configure, Price, Quote (CPQ) tool that automates price quoting with detailed, location-based insights. The company's services cater to a range of sectors, including local exchange carriers, cable companies, competitive local exchange carriers, and municipal networks, enabling them to improve their marketing investments and operational outcomes.
Sidecar Interactive, Inc. is an e-commerce technology company that specializes in providing software solutions for retailers to enhance their online marketing efforts. The company's primary offering is the Sidecar Predictive Bid Engine, which optimizes advertising bids for intelligent product groupings based on real-time data analysis. This system ensures that products receive appropriate bids to maximize visibility and return on advertising spend, while also allowing high-performing products to be managed individually. Additionally, Sidecar's solutions include dynamic product advertisements on social media platforms, enabling retailers to showcase their entire product catalogs effectively. By leveraging machine learning and extensive data analytics, Sidecar assists online retailers in managing their product listing advertisement campaigns, ultimately improving business performance and efficiency. Founded in 2007 and based in Philadelphia, Pennsylvania, Sidecar was previously known as Snipi, Inc. until its name change in 2011.
Menlo Security, Inc. is a cybersecurity company that offers a cloud-based isolation platform designed to protect organizations from cyberattacks by eliminating malware threats from websites, documents, and emails. The platform safely executes all web content in the cloud, allowing users to interact with online resources without risk. Menlo Security serves a diverse clientele, including Fortune 500 companies and financial services institutions, through a network of resellers both in the United States and internationally. Founded in 2012 and headquartered in Mountain View, California, the company has expanded its operations across various regions, including North America, EMEA, Australia, New Zealand, Japan, APAC, and DACH. The firm has received backing from notable investors, indicating strong confidence in its innovative approach to cybersecurity.
Everactive's custom ultra-low-power chips enable completely battery-less wireless sensors that form the foundation of end-to-end IoT data services. The company technology allows for low cost, long-lived, and intelligent instrumentation of industrial operations. Its end-to-end solutions are built upon innovative advances in ultra-low-power circuit design and wireless communication that enable the company to power its Eversensors exclusively from harvested energy. The company also creates networking and cloud software to provide a service focused on providing customers with valuable insights from generated and self-sustaining data streams. The company was founded on 2012 and is based in Santa Clara, California.
Artizan Biosciences develops small molecule drugs targeting human diseases, utilizing its IgA-SEQ technology platform to identify disease-driving bacteria within the intestinal microbiota. Founded in 2016 and headquartered in New Haven, Connecticut, the company focuses on creating new and potentially curative treatments. With a commitment to advancing pharmaceutical drug development, Artizan Biosciences aims to address unmet medical needs through innovative approaches in biotechnology.
SiFive, Inc. is a semiconductor company that specializes in designing and manufacturing chips, particularly focused on RISC-V architecture. Founded in 2015 and headquartered in San Mateo, California, with additional offices worldwide, SiFive develops multi-core application processors, embedded microcontrollers, and system-on-chip (SoC) products tailored for various applications, including IoT and wearables. The company provides software development kits, toolchains, and utilities to facilitate the development of RISC-V devices, enhancing the efficiency and affordability of hardware design. By leveraging open-source principles and software automation, SiFive aims to accelerate innovation in the semiconductor industry, enabling both large and small businesses to bring new hardware solutions to market more rapidly.
Full Measure Education, Inc. is a company that specializes in student lifecycle and retention management through a mobile engagement platform designed for higher education institutions. Incorporated in 2013 and based in Washington, D.C., the company offers a mobile application that provides students with access to their information and the ability to manage administrative needs. Full Measure Education combines technology with human-powered services to enhance student retention and reduce dropout rates, drawing from extensive experience gained through over 10 million student help desk interactions across more than 850 colleges and universities. The platform includes features such as messaging, custom auto-responses, campaign management, data reporting, and content management, facilitating support for students from admission through to graduation.
Algorithmia, Inc. is a Seattle-based company that provides a platform for deploying and managing machine learning models, focusing on automating the MLOps process for organizations. Founded in 2013, Algorithmia enables developers and data scientists to explore, create, and share algorithms as web services, facilitating the integration of machine learning into various applications. The platform supports popular frameworks such as TensorFlow, PyTorch, Scikit-learn, and MXNet, and can handle a high volume of concurrent algorithm requests. Additionally, Algorithmia hosts a public marketplace for algorithms, offering enterprise customers a reliable solution for their mission-critical workloads.
DrayNow, Inc., founded in 2017 and based in Pipersville, Pennsylvania, operates as a technology company specializing in the intermodal freight sector. It offers a real-time online marketplace that connects intermediaries with carriers, facilitating the efficient management of intermodal freight transportation. By leveraging advanced technology, DrayNow enables users to maintain constant visibility of shipments, compare rates, view load details, and select available loads in real-time. This innovative platform optimizes the first and last mile of intermodal logistics, enhancing operational efficiency and helping companies achieve higher levels of capacity, service, and profitability.
LunaPBC, Inc. operates a community-owned platform focused on health and DNA research. The company offers LunaDNA, a database that facilitates the sharing of health and genetic data for medical research. This platform supports health research initiatives by both non-profit and for-profit organizations, contributing to medical discoveries. LunaPBC operates as a Public Benefit Corporation, emphasizing community welfare by allowing individuals to share their health data, which in turn drives research and innovation. Additionally, members of the platform have the opportunity to share in the earnings derived from medical advancements, promoting a sense of shared ownership and benefit within the community. Founded in 2017 and based in San Diego, California, LunaPBC aims to advance genomic and medical research while prioritizing the interests of its contributors.
LunaDNA is a community-owned platform that facilitates the sharing of health and DNA data for medical research. Founded by the creators of Illumina, a leader in DNA sequencing, LunaDNA addresses the issue of siloed genomic data by providing individuals with a compelling incentive to share their health information. Participants are rewarded with shares in the database, allowing them to benefit from the profits generated by medical research and discoveries. This model not only empowers users to contribute their health records, genomic data, and personal health experiences but also fosters a sense of community ownership. As researchers pay to access the data for their studies, the proceeds are distributed back to the community, akin to dividends. By prioritizing privacy and trust, LunaDNA aims to increase participation in genomic research while facilitating advancements in healthcare that can ultimately save lives.
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraines. The company's primary product candidate, STS101, is a drug-device combination featuring a proprietary dry-powder formulation of dihydroergotamine mesylate. This medication is designed for self-administration using a pre-filled, single-use nasal delivery device. Currently, STS101 is undergoing Phase III clinical trials, marking a significant step in its development process. Founded in 2016 and based in South San Francisco, California, Satsuma Pharmaceuticals aims to provide effective solutions for individuals suffering from acute migraine attacks.
Arrakis Therapeutics is a biopharmaceutical company focused on developing innovative drugs that target ribonucleic acid (RNA) to treat a variety of diseases, including cancer and rare genetic disorders. The company employs a unique drug discovery platform that integrates advanced RNA bioinformatics and structural tools, allowing it to identify new RNA targets and create RNA-targeted small molecules (rSMs). Its proprietary pipeline consists of these rSMs aimed at genetically validated targets across multiple disease areas. Additionally, Arrakis offers SHAPEware, a software tool that assists in predicting RNA secondary structures and potential ligand-binding sites. Founded in 2015 and based in Waltham, Massachusetts, Arrakis Therapeutics aims to enhance therapeutic options for patients through its cutting-edge research and development efforts.
The leading provider of cyber risk management software, RiskLens empowers business executives, risk officers and CISOs to manage their organization's cyber risk from the business perspective by quantifying it in financial terms. RiskLens was founded in 2011 and is headquartered in Spokane, Washington.
Hyalex Orthopaedics, Inc. is a medical device company based in Lexington, Massachusetts, focused on developing innovative products that utilize HYALEX technology, a synthetic polymer engineered to mimic cartilage. Founded in 2016, the company specializes in creating a biomimetic material that can effectively simulate healthy cartilage to treat diseased or damaged joints. The unique properties of HYALEX allow it to maintain low friction and wear, even under the significant loads typically experienced in human joints. This capability enables surgeons to replace arthritic cartilage while preserving healthy bone. Although Hyalex Orthopaedics is advancing its product development, its offerings have not yet received approval for use in humans from any regulatory agency.
MarginEdge Co. develops food and beverage tracking and analytics software for restaurants. It offers MarginEdge, a software solution for invoice management, recipe and product pricing, and food costs optimization. The company’s software also automates processes, connects systems; and streamlines key activities, such as inventory, cost-tracking, ordering, and recipes. MarginEdge Co. was formerly known as Invioso Co. The company was founded in 2015 and is based in Falls Church, Virginia.
Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.
KenSci's machine learning powered risk prediction platform helps healthcare providers and payers intervene early by identifying clinical, financial and operational risk to save costs and lives. KenSci's platform is engineered to ingest, transform and integrate healthcare data across clinical, claims, and patient-generated sources. With a library of pre-built models and modular solutions, KenSci's machine learning platform to integrates into existing workflows allowing health systems to better identify utilization, variation and improve hospital operations. With Explainable AI models for healthcare, KenSci is making risk-based prediction more efficient and accountable.
Seismos, the K-wave Company™, is a data analytics company for production optimization providing proprietary solutions enabling real-time, underground fluid flow monitoring, inside the reservoir, during production. Monitoring fluid movement with conventional seismic technologies requires months for data acquisition and processing, disrupts production and costs millions. Seismos breaks this paradigm and solves all problems associated with conventional methods by providing real-time information, at a fraction of the cost, through its proprietary, cloud-based K-wave technology that is non-invasive to production and to surface operations.